Abstract: An integrated fluidic device is employed to perform microbial cell separation, in situ microcolony growth, and optional identification and antimicrobial susceptibility testing. While the integrated fluidic device is maintained in a closed state, microbial cell separation is performed to provide a microbial cell suspension that is contacted with a solid phase growth medium. A liquid component of the suspension is removed, thereby retaining microbial cells on the growth medium for incubation, growth, and subsequent harvesting and characterization. In some embodiments, antimicrobial susceptibility testing is performed by contacting growth media with a solid support having an antimicrobial agent provided thereon, such that the antimicrobial agent diffuses into a subregion of the growth medium that is accessible through an aperture surrounded, at least in part, by the solid support.

Abstract: Methods and compositions are provided for the selective lysis of eukaryotic cells and the separation of microbial cells. Blood cells and/or other eukaryotic cells in a sample, may be selectively lysed by adding, to the sample, a blood lysis reagent including saponin and an alkaline buffer, and optionally sodium polyanethole sulfonate and a non-ionic surfactant, thereby forming a mixture, and agitating the mixture. Microbial cells in the mixture may then be separated, for example, using a separation method such as centrifugation or filtration, and optionally detected or cultured in growth media. Blood lysis reagent compositions are provided that are suitable for preserving the intactness of microbial cells upon mixing with the sample. In example embodiments in which the sample is a blood sample, the blood lysis reagent composition may be selected to avoid or reduce the presence of visible blood debris upon centrifugation or filtration.

Abstract: The present invention relates to compounds that are useful as inhibitors of protein arginine methyltransferase that have a formula selected from Formula (I), Formula (II) and Formula (III), as well as racemic mixtures, diastereomers, enantiomers and tautomers thereof and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof as defined herein. The compound are useful as inhibitors of PRMTs and/or CARM-I. The invention further relates to compositions comprising such compounds and methods for their use.

Abstract: The present invention relates to compounds that are useful as inhibitors of protein arginine methyltransferase that have a formula selected from Formula (I), Formula (II) and Formula (III), as well as racemic mixtures, diastereomers, enantiomers and tautomers thereof and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof as defined herein. Said compound are useful as inhibitors of PRMTs and/or CARM-I. The invention further relates to compositions comprising such compounds and methods for their use.

Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I), and racemic and scalemic mixtures, diastereomers and enantiomers thereof: or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt, prodrug or complex thereof, wherein Y, L, Z, W, M, Ra, Rb and Rc are as defined in the specification.

Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.